 | |
| Clinical data | |
|---|---|
| Trade names | Bevyxxa, Dexxience, other |
| Other names | PRT054021, PRT064445 |
| AHFS/Drugs.com | Monograph |
| Routes of administration | By mouth |
| Drug class | Anticoagulant (direct factor Xa inhibitor)[1] |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Protein binding | 60% |
| Elimination half-life | 19–27 hrs |
| Duration of action | ≥72 hrs |
| Excretion | 85% feces, 11% urine |
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C23H22ClN5O3 |
| Molar mass | 451.905 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Betrixaban, sold under the brand name Bevyxxa among others, was an anticoagulant used to prevent blood clots in veins in at risk adults, hospitalized for an illness.[2] It has a higher rate of bleeding compared to enoxaparin.[3] It was taken by mouth.[2]
Common side effects include bleeding.[1] Other side effects may include allergic reactions.[1] Safety in pregnancy is unclear.[1] It is a direct factor Xa inhibitor.[1]
Betrixaban was approved for medical use in the United States in 2017; however, has been subsequently discontinued.[1] It was refused approval in Europe in 2018 due to concerns regarding effectiveness and safety.[3]
References edit
- ^ a b c d e f g h "Betrixaban Monograph for Professionals". Drugs.com. Archived from the original on 25 January 2021. Retrieved 10 January 2022.
- ^ a b Research, Center for Drug Evaluation and. "Approved Drugs - FDA approved betrixaban (BEVYXXA, Portola) for the prophylaxis of venous thromboembolism (VTE) in adult patients". www.fda.gov. Archived from the original on 2018-07-25. Retrieved 2018-10-29.
- ^ a b "Dexxience". Archived from the original on 10 April 2021. Retrieved 10 January 2022.